不同剂量瑞舒伐他汀对急性非ST段抬高型心肌梗死患者全血P-选择素的影响

Effects of Rosuvastatin on P-selectin in Patients with Non ST-segment Elevation Acute Myocardial Infarction

目的:观察急性非ST段抬高型心肌梗死患者全血P-选择(Ps)的水平,探讨瑞舒伐他汀对Ps的影响。方法:选择96例急性非ST段抬高型心肌梗死患者作为病例组,随机将其分为10mg瑞舒伐他汀组57例和5mg瑞舒伐他汀组39例,同时选择22例健康者作为对照组。所有研究对象均流式细胞仪法检测全血Ps水平。病例组于入院即刻分别给予瑞舒伐他汀10mg、5mg口服,以后分别给予10mg/(kg·d)、5mg/(kg·d)口服治疗4周后复查,同时观察药物不良反应。结果:1不同剂量瑞舒伐他汀治疗组均无不良反应出现。2病例组全血Ps水平较健康对照组明显升高,差别有统计学意义(P<0.05)。310mg瑞舒伐他汀组治疗后全血Ps水平较治疗前明显下降,差别有统计学意义(P<0.05);5mg瑞舒伐他汀组治疗后全血Ps水平较治疗前差别无统计学意义(P>0.05)。410mg瑞舒伐他汀组治疗后全血Ps水平较5mg瑞舒伐他汀组明显下降,差别有统计学意义(P<0.05)。结论:瑞舒伐他汀10mg/(kg·d)可降低急性非ST段抬高型心肌梗死患者全血Ps水平,从而防治血栓形成。

Objective Toobserve level of P-selection（Ps） in patients with NSTEMI, and to study the effects of rosuvastatin on Ps. Methods： 96 patientswith NSTEMI were divided randomly into two groups： the rosuvastatin 10mg dose group（n=57） and rosuvastatin 5mg dose group（n=39）. 22 healthysubjects were taken as contro1 group, whose age and sex were matched with the above two groups.The level of Ps was detected by flow cytometryfor each group. The indexes were measured again after 4 weeks of treatment of rosuvastatin, and the adverse effect was observed. Results： ①Therewere no adverse effectsin both groups. ②The level of Ps in patients with NSTEMI washigher than that ofcontro1 group （P〈0.05）. ③The level of Ps in10mg dose group decreased significantly after treatment（P〈0.05）, and there was no significantdifference in 5mg dose group（P〉0.05）. ④Thelevel ofPs in 10mg dose group decreased significantly compared with that of 5mg dose group after treatment （P〈0.05）. Conclusions： Rosuvastat10mg/（kg·d）could depress the level of Ps in patients with NSTEMI, and it could prevent and cure the thrombosis.